“Wound Debridement Market is expected to Reach $1.92 Billion By 2029”, says Visiongain report

08 January 2020
Pharma

Visiongain’s new report the Wound Debridement Market Report 2019-2029: Forecasts by Product (Gels, Ointments & Creams, Surgical Devices, Medical Gauzes, Mechanical Debridement Pads, Ultrasonic Devices, Others), by Wound Type (Venous Leg Ulcers, Diabetic Foot Ulcers, Pressure Ulcers, Surgical & Traumatic Wounds, Burns, Others), by Method (Autolytic Methods, Enzymatic Methods, Surgical Methods, Mechanical Methods, Others), by End User (Hospitals, Clinics, Others), plus analysis of leading companies operating in the global wound debridement market.

Increasing prevalence of diabetes and associated wounds, rising aging population in developed as well as developing economies, increasing incidences if burn injuries and increasing awareness regarding wound care management are expected to spur global wound debridement market over the forecast period. In 2019, the global wound debridement market was valued at $830 million and is expected to reach $1.92 billion by 2029 at a healthy growth rate of 8.7%.

Growing incidences of diabetes, pressure ulcers, and other chronic diseases are encouraged wound care management providers over the past few years and the trend is expected to continue over the coming years. According to the World Health Organization, in 1980, the number of people diagnosed with diabetes was nearly 108 million and this figure has increased to more than 450 million in 2018. Additionally, a hectic lifestyle, increasing working hours, and an unhealthy diet has resulted in increased prevalence of diabetes in the young population. For instance, according to the World Health Organization, the global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to more than 9% in 2018.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

Read

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

Read

Visiongain Publishes Clinical Perinatal Software Market Report 2020-2030

Various research studies are currently underway, which are expected to create a competitive advantage for manufacturers to develop new and innovative and advanced software that is expected to provide a variety of additional opportunities in the perinatal clinical software market.

01 July 2020

Read

Visiongain publishes Clinical Laboratory Tests Market Report 2020-2030

Growing investment in target diagnosis of cardiovascular disorders, TB and diabetes drives demand for clinical laboratory testing. Clinical lab tests help in diagnosing mellitus diabetes. According to the International Diabetes Federation article published in 2019, some 463 million adults were diabetic, and it is estimated that it will reach 700 million worldwide by 2045.

01 July 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever